[18F] Sodium Fluoride Dose Reduction Enabled by Digital Photon Counting PET/CT for Evaluation of Osteoblastic Activity

Maria I. Menendez*, Richard R. Moore1, Mahmoud Abdel-Rasoul2, Chadwick L. Wright1, Soledad Fernandez2, Rebecca D. Jackson3 and Michael V. Knopp1

1 Department of Radiology, The Wright Center of Innovation in Biomedical Imaging, The Ohio State University Wexner Medical Center, Columbus, OH, United States, 2 Center for Biostatistics, College of Medicine, The Ohio State University, Columbus, OH, United States, 3 Department of Internal Medicine, Endocrinology, Diabetes and Metabolism, The Ohio State University Wexner Medical Center, Columbus, OH, United States

The aim of the study was to assess the quality and reproducibility of reducing the injected [18F] sodium fluoride ([18F]NaF) dose while maintaining diagnostic imaging quality in bone imaging in a preclinical skeletal model using digital photon counting PET (dPET) detector technology. Beagles (n = 9) were administered three different [18F]NaF doses: 111 MBq (n = 5), 20 MBq (n = 5), and 1.9 MBq (n = 9). Imaging started ≃45 min post-injection for ≃30 min total acquisition time. Images were reconstructed using Time-of-Flight, ultra-high definition (voxel size of 1 × 1 × 1 mm3), with 3 iterations and 3 subsets. Point spread function was modeled and Gaussian filtering was applied. Skeleton qualitative and quantitative molecular image assessment was performed. The overall diagnostic quality of all images scored excellent (61%) and acceptable (39%) by all the reviewers. [18F]NaF SUVmean showed no statistically significant differences among the three doses in any of the region of interest assessed. This study demonstrated that a 60-fold [18F]NaF dose reduction was not significantly different from the highest dose, and it had not significant effect on overall image quality and quantitative accuracy. In the future, ultra-low dose [18F]NaF dPET/CT imaging may significantly decrease PET radiation exposure to preclinical subjects and personnel.

Keywords: [18F] sodium fluoride, PET/CT, digital photon counting, bone imaging, bone metabolism, sodium fluoride dose reduction, preclinical molecular imaging, canine PET

INTRODUCTION

Sodium Fluoride ([18F]NaF) Positron Emission Tomography—Computed Tomography (PET/CT) is used clinically on oncology patients to detect and characterize osteoblastic metastatic lesions (1–4), as well as to aid visualization of atherosclerotic calcifications and plaques in patients with cardiovascular disease (5–7). Recently, [18F]NaF has also been used as a bone imaging biomarker to assess and quantify bone metabolic processes (i.e., osteoblastic activity) in non-oncologic musculoskeletal disorders such as osteoarthritis and osteoporosis (8–20). The radiolabeled fluoride ion exchanges with the hydroxyl groups in hydroxyapatite crystals on the surface of the bone matrix to form fluoroapatite. Therefore, uptake of [18F]NaF uptake can be used a marker of osteoblastic...
bone metabolism. $[^{18}F]NaF$ PET/CT imaging is a sensitive, noninvasive, imaging approach to assess bone metabolism (21–23). Due to its $[^{18}F]NaF$ favorable pharmacokinetics, such as high bone uptake, minimal binding to serum proteins, rapid single-pass extraction, and fast clearance from the soft tissues, $[^{18}F]NaF$ PET is more sensitive for detecting abnormal osteoblastic activity and lesions than the current clinical gold standard, $^{99m}$Tc-Technetium-labeled methylene diphosphonate ($^{99m}$Tc-MDP) gamma scintigraphy. When compared with $^{99m}$Tc-MDP gamma scintigraphy, $[^{18}F]NaF$ PET has higher sensitivity, superior image resolution, and improved target-to-background ratio (24). Hybrid imaging modalities such as PET/CT and PET/Magnetic Resonance Imaging (MRI) are currently used for assessing bone metabolism (22–25). PET/MRI presents operational challenges including attenuation correction for PET, longer than desired MRI image acquisition times when compared with CT, and reduced field of view when using dedicated MRI coils (e.g., knee coils) which fail to aid in whole body skeletal assessment (25–27).

Radiation exposure can be a concern due to ionizing radiation from PET radiotracers (28). Minimizing radiation exposure is important not only for research subjects and patients, but also for imaging technologists, nursing personnel and subject/patient caregivers. It is believed that significant reductions in PET radiotracer doses will benefit pediatric subjects/patients and those subjects/patients participating in longitudinal studies with multiple serial PET studies by reducing cumulative radiation exposure (29, 30). Many imaging studies have focused on CT radiation dose reduction without addressing the potential dose reduction strategies associated with the administered PET radiotracers (31, 32). Most PET radiotracer dose reduction has been focused on the widely clinically utilized radiotracer: 2-deoxy-2-$[^{18}F]$-fluoro-D-glucose ($[^{18}F]$FDG) (33–36). The current recommended guidelines for human $[^{18}F]NaF$ injected doses from the European Association of Nuclear Medicine (EANM) are weight based. For Adults: 1.5–3.7 MBq/kg (megabecquerel (MBq) per kilogram (kg) of body weight (BW), and Pediatrics: 2.2 MBq/kg (37). The Society of Nuclear Medicine and Molecular Imaging (SNMMI) guidelines recommend a fixed dose for adults: 185–370 MBq, and weight-based for Pediatrics (2.22 MBq/kg) (38). Some clinical studies have examined $[^{18}F]NaF$ dose reduction and reported no effect on image quality (30, 39–41). However, comprehensive preclinical $[^{18}F]NaF$ dose reduction studies in translational large animal models and its impact on overall PET image quality are missing.

The recent introduction of clinically approved PET/CT systems equipped with digital photon counting PET (dPET) detector technology enables new PET imaging approaches for addressing PET radiotracer dose reduction, faster PET image acquisition times, and higher definition in PET image reconstruction (42, 43). Digital photon counting PET detector technology enables ultra-high definition reconstruction with voxel volume of $1 \times 1 \times 1$ mm$^3$ and more precisely localizes PET annihilation events (i.e., reduces partial volume effects) which improve quantitative PET accuracy for imaging biomarker assessment (44–46). Additionally, lower PET doses can be implemented in dPET imaging in accordance with ALARA (As Low as Reasonably Achievable) while maintaining diagnostic imaging quality (47–49). With the recent advances in dPET detector technology, there is an immediate opportunity to minimize PET radiotracer doses in preclinical research subjects imaged on these clinical dPET/CT systems and likewise reduce radiation exposures to PET staff and handling personnel. This study is an important step to develop and standardize low-dose hybrid PET/CT imaging methodologies in preclinical imaging, and to provide guidance for future clinical studies, and clinical trials applying $[^{18}F]NaF$ PET dose reduction.

The aim of the study was to assess the quality and reproducibility of reducing the injected $[^{18}F]NaF$ activity while maintaining diagnostic imaging quality in bone imaging in a preclinical skeletal model using digital photon counting PET (dPET) detector technology.

We hypothesized that 5- to 60-fold reductions in administered $[^{18}F]NaF$ activity would provide equivalent image quality on dPET/CT when compared with the standard $[^{18}F]NaF$ doses.

MATERIALS AND METHODS

Animals

This study was conducted according to NIH guidelines, and according to protocols approved by the Institutional Animal Care and Use Committee (IACUC) of The Ohio State University. Nine healthy skeletally mature male beagles [weight (kg) mean ± SEM; 15 ± 4.7] were used.

Positron Emission Tomography/Computed Tomography Acquisition

Subjects underwent general anesthesia induced by acepromazine [Aceph, Henry Schein Animal Health, Dublin OH; intravenously (IV), 0.1 mg/kg], ketamine (Ketasthesia; Henry Schein Animal Health, Dublin OH; IV, 10 mg/kg), and diazepam (Hospira; Lake Forest, IL; IV, 0.25 mg/kg) and maintained by isoflurane (Isothesia; Henry Schein Animal Health, Dublin, OH; 1–4%). The subjects were place in supine position with the front and distal extremities extended and supported in a custom-made multimodal imaging positioning device to mimic human scans and to improve the precision and positional consistency among scans (13, 50). Subjects were intravenously administered 3 different $[^{18}F]NaF$ target doses: 111 MBq (standard dose/SD; $n = 5$), 20 ± 7.8 MBq [mean ± standard error of the mean (SEM); low dose/LD; $n = 5$], and 1.9 MBq (ultra-low dose/ULD; $n = 9$) (see Table 1).

All imaging was performed using the Vereos dPET/CT system (Philips, Cleveland, Ohio). A low-dose computed tomography (CT) scan was performed for attenuation correction and coregistration. For the low dose (LD) and ultra-low dose (ULD), whole-body PET imaging began at ~45 min post-injection using acquisitions times of 180 s/bed position in list-mode for 10 bed positions (total dPET image acquisition time ~30 min). The standard dose (SD) ($n = 5$) began at ~30 min and was acquired with 120 sec/bed. All SD dPET acquisitions were retrospectively list-mode clipped from 120 s/bed to 4 s/bed to simulate the same count density as ULD. In addition, all LD dPET acquisitions were retrospectively list-mode clipped from 180 s/bed to 18 s/bed to simulate the same count density.
### TABLE 1 | Dogs and corresponding standard (SD), low (LD) [mean ± standard error of the mean (SEM)], and ultra-Low (ULD) [18F]NaF doses.

| Dog | Standard dose (111 MBq) | Low dose (20 ± 7.8 MBq) | Ultra-low dose (1.9 MBq) |
|-----|-------------------------|-------------------------|--------------------------|
| 111 | X                       | X                       | X                        |
| 112 | X                       | X                       | X                        |
| 113 | X                       | X                       | X                        |
| 114 | X                       | X                       | X                        |
| 115 | X                       | X                       | X                        |
| 116 | X                       | X                       | X                        |
| 117 | X                       | X                       | X                        |
| 118 | X                       | X                       | X                        |
| 107 | X                       |                          |                          |

as ULD. All list-mode clipped SD, list-mode clipped LD, and ULD acquisitions were reconstructed using Time-of-Flight and ultra-high-definition (voxel volume = 1 × 1 × 1 mm³), three iterations, and three subsets. Point spread function (PSF) was modeled and Gaussian filtering was applied (Figures 1, 2) (Supplementary Material).

### Qualitative Image Analysis

Philips Intellispace Portal was used to generate the images for subsequent review by a blinded reader panel using REDCap survey platform. Each dPET scan was presented with three non-rotating maximum intensity projection (MIP) images, with 0° (ventral projection), 108° (right posterior oblique projection) and −90° (left lateral projection) angles, with a PET SUV window level of 0–10. REDCap surveys recorded the reader assessment of [18F]NaF dPET image quality (Figure 1). The images were reviewed by three authors (CW, MVK, MIM) working independently and blinded to radiotracer dose administered. Reviewers performed imaging assessment of the entire imaging dataset twice with at least 1 week between reader assessments to control for visual memory. The image datasets were randomly ordered between surveys.

Qualitative reader assessment outcome parameters included: overall diagnostic quality of the images, and regional bone [18F]NaF uptake of the following regions of interest (ROI): cervical, thoracic, and lumbar, spine, skull, proximal long bones (scapula, humerus, and radius and ulna), distal long bones (femur, tibia, and pelvis), short bones (carpal joint bones, metacarpal bones, tarsal joint bones, metatarsal bones, proximal, middle, and distal phalanges) (Table 2).

The qualitative [18F]NaF uptake was scored 1–4 (1 = not acceptable; 2 = insufficient; 3 = acceptable; 4 = excellent).

### Semi-Quantitative Image Analysis

Maximum and mean standardized uptake values (SUV$_{max}$ and SUV$_{mean}$) for [18F]NaF activity were assessed using two-dimensional (2D) ROI, manually traced over representative...
osseous structures including mandible, carpus, first lumbar vertebral body, distal femur, tarsus, caudal vertebrae, and a region of the liver (Tables 3, 4).

**Statistical Analysis**

Reviewer ratings of images are reported as rating frequencies and percentages for each ROI are represented in Table 2. Continuous outcome variables for dPET: SUV\textsubscript{max} and SUV\textsubscript{mean} were modeled using linear mixed models with random intercepts and categorical fixed effects representing dose (Tables 3, 4). The random intercepts account for correlation between repeated measures on each canine. Results are reported as model based estimated means and 95% confidence intervals. Overall p-values for groups effects are also reported. All hypothesis tests were conducted at a 5% type I error level. All statistical analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC).

**RESULTS**

All dPET/CT imaging studies were completed and all dPET image datasets (n = 19) were deemed evaluable.

**Qualitative Image Analysis**

The overall diagnostic quality of all images was scored as excellent (61%) and acceptable (39%) by the three reviewers (Table 2). The skull images scored excellent (66%) and acceptable (34%). Both thoracic and lumbar spine images were scored excellent (98%) and acceptable (2%). The proximal long bones images were scored excellent (61%) and acceptable (39%). Cervical spine images were scored excellent (43%), acceptable (54%), and insufficient (4%). Distal long bones images were scored excellent (41%), acceptable (58%), and insufficient (1%). Short bones images were scored excellent (46%), acceptable (52%), and insufficient (2%). Only between 1 and 4% of the cervical spine, distal long bones, and short bones images were scored as insufficient [\textsuperscript{18}F]NaF uptake compared to 96–99% acceptable and excellent uptake scores. None of the ROI images were scored as not acceptable. Table 2 summarizes the reviewer’s score frequency for each skeletal ROI.

**Semi-Quantitative Image Analysis**

Sodium fluoride ([\textsuperscript{18}F]NaF) SUV\textsubscript{mean} showed no statistically significant differences among the three doses (SD, LD, and ULD) in any of the osseous structures assessed (i.e., mandible, carpus, first lumbar vertebra, distal femur, tarsus, caudal vertebrae, and a region of the liver) (Table 3). For the [\textsuperscript{18}F]NaF SUV\textsubscript{max} (Table 4), only the first lumbar vertebra showed statistically significant differences among the three doses with the SUV\textsubscript{max} at SD significantly lower than the SUV\textsubscript{max} values at LD (p < 0.03) and ULD (p < 0.02). The mandible, carpus, distal femur, tarsus, caudal vertebrae, and a region of the liver showed no statistically significant differences among the three doses.

**DISCUSSION**

This study demonstrates that a 60-fold sodium fluoride ([\textsuperscript{18}F]NaF) dose (ULD) reduction did not significantly differ in image quality and quantification compared to the standard dose (SD) in a healthy canine model. Our findings present a feasible option to markedly reduce [\textsuperscript{18}F]NaF radiotracer doses...
TABLE 2 | Qualitative image analysis as score frequencies and percentages (%) for the overall image quality and the skeletal regions of interest using standard (SD), low (LD), and ultra-low (ULD) $^{[18]}$F$\text{NaF}$ doses.

| Region of interest | Score          | Standard dose (111 MBq) | Low dose (20 MBq) | Ultra-low dose (1.9 MBq) |
|--------------------|----------------|------------------------|-------------------|-------------------------|
| Overall image quality | Excellent | 25 (62.5%) | 24 (60.0%) | 39 (54.2%) |
|                     | Acceptable | 15 (37.5%) | 16 (40.0%) | 33 (45.8%) |
|                     | Insufficient | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
|                     | Not acceptable | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Cervical spine | Excellent | 16 (40.0%) | 20 (50.0%) | 34 (47.2%) |
|                     | Acceptable | 22 (55.0%) | 18 (45.0%) | 38 (52.8%) |
|                     | Insufficient | 2 (5.0%) | 2 (5.0%) | 0 (0.0%) |
|                     | Not acceptable | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Thoracic spine | Excellent | 40 (100.0%) | 39 (97.5%) | 69 (97.2%) |
|                     | Acceptable | 0 (0.0%) | 1 (2.5%) | 2 (2.8%) |
|                     | Insufficient | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
|                     | Not acceptable | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Lumbar spine | Excellent | 40 (100.0%) | 39 (97.5%) | 70 (97.2%) |
|                     | Acceptable | 0 (0.0%) | 1 (2.5%) | 2 (2.8%) |
|                     | Insufficient | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
|                     | Not acceptable | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Skull | Excellent | 15 (37.5%) | 15 (38.5%) | 27 (37.5%) |
|                     | Acceptable | 25 (62.5%) | 24 (61.5%) | 45 (62.5%) |
|                     | Insufficient | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
|                     | Not acceptable | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Proximal long bones | Excellent | 18 (45.0%) | 17 (42.5%) | 28 (38.9%) |
|                     | Acceptable | 22 (55.0%) | 23 (57.5%) | 44 (61.1%) |
|                     | Insufficient | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
|                     | Not acceptable | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Distal long bones | Excellent | 19 (47.5%) | 19 (48.7%) | 27 (37.5%) |
|                     | Acceptable | 21 (52.5%) | 20 (51.3%) | 42 (58.3%) |
|                     | Insufficient | 0 (0.0%) | 0 (0.0%) | 3 (4.2%) |
|                     | Not acceptable | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Short bones | Excellent | 20 (50.0%) | 20 (50.0%) | 32 (44.4%) |
|                     | Acceptable | 20 (50.0%) | 16 (40.0%) | 40 (55.6%) |
|                     | Insufficient | 0 (0.0%) | 4 (10.0%) | 0 (0.0%) |
|                     | Not acceptable | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |

Reviewer’s scores are combined.

in a translational preclinical system of bone imaging using a dPET/CT system without loss of overall imaging quality.

Regardless of the $^{[18]}$F$\text{NaF}$ dose, the overall dPET image quality assessment demonstrated diagnostic image quality in all $^{[18]}$F$\text{NaF}$ dPET image data sets with 61% of the scans scored as excellent and 39% scored as acceptable. No dPET imaging study received an insufficient or not acceptable score. These results indicate that ULD $^{[18]}$F$\text{NaF}$ dPET image quality was comparable to SD and even LD $^{[18]}$F$\text{NaF}$ dPET images (Table 2). ULD imaging is readily achieved with the new dPET detector capabilities enabled by improved spatial and temporal resolutions, reduced dead time, and higher dynamic count rate range when compared with conventional, analog photomultiplier tube-based PET (cPET) detectors which has been previously described (43, 45, 46, 51, 52). In existing cPET systems, multiple scintillation crystals are coupled to multiple photomultiplier tube-based detectors whereas each scintillation crystal is coupled 1:1 with a single digital photon counting dPET detector. Hence, the combination of the direct coupling (1:1), with the enhanced time of flight (TOF) improves the timing and volumetric resolutions of the digital over the analog PET (111 MBq).

TABLE 3 | $^{[18]}$F$\text{NaF}$ mean standardized uptake values (SUV$_{\text{mean}}$) of regions of interest (ROIs).

| ROI          | Standard dose (111 MBq) | Low dose (20 MBq) | Ultra-low dose (1.9 MBq) | Overall p-value |
|--------------|------------------------|-------------------|-------------------------|----------------|
| First lumbar | Mean (95% CI)          | Mean (95% CI)     | Mean (95% CI)           | 0.0380         |
| Distal femur | 14.8 (11.7, 17.9)      | 16.5 (15.6, 17.7) | (17.3, 22.2)           | 0.1025         |
| Carpus       | 7.2 (5.4, 9.1)         | 7.7 (7.5, 9.8)    | 7.2 (5.8, 8.6)          | 0.8961         |
| Mandible     | 6.9 (5.6, 8.2)         | 7.4 (6.5, 8.9)    | 8.6 (7.8, 9.6)          | 0.0821         |
| Tarsus       | 6.9 (5.1, 7.7)         | 6.1 (5.1, 7.2)    | 6.1 (5.1, 7.2)          | 0.3149         |
| Caudal vertebrae | 6.5 (4.2, 8.5) | 6.2 (4.5, 7.9)    | 6.2 (4.5, 7.9)          | 0.9961         |

| ROI          | Standard dose (111 MBq) | Low dose (20 MBq) | Ultra-low dose (1.9 MBq) | Overall p-value |
|--------------|------------------------|-------------------|-------------------------|----------------|
| Liver        | 0.7 (0.4, 1.0)         | 0.6 (0.3, 1.0)    | 1.0 (0.8, 1.2)          | 0.1428         |

TABLE 4 | $^{[18]}$F$\text{NaF}$ maximum standardized uptake values (SUV$_{\text{max}}$) of regions of interest (ROIs).

| ROI          | Standard dose (111 MBq) | Low dose (20 MBq) | Ultra-low dose (1.9 MBq) | Overall p-value |
|--------------|------------------------|-------------------|-------------------------|----------------|
| First lumbar | 14.8 (11.7, 17.9)      | 16.5 (15.6, 17.7) | (17.3, 22.2)           | 0.1025         |
| Distal femur | 4.6 (3.8, 5.3)         | 4.1 (3.1, 5.0)    | 3.6 (3.0, 4.3)          | 0.1025         |
| Carpus       | 7.2 (5.4, 9.1)         | 7.7 (7.5, 9.8)    | 7.2 (5.8, 8.6)          | 0.8961         |
| Mandible     | 6.9 (5.6, 8.2)         | 7.4 (6.5, 8.9)    | 8.6 (7.8, 9.6)          | 0.0821         |
| Tarsus       | 6.3 (4.9, 7.7)         | 7.4 (6.0, 8.8)    | 6.1 (5.1, 7.2)          | 0.3149         |
| Caudal vertebrae | 6.5 (4.2, 8.5) | 6.2 (4.5, 7.9)    | 6.2 (4.5, 7.9)          | 0.9961         |

$^{[18]}$F$\text{NaF}$, sodium fluoride; CI, confidence intervals. *p < 0.05 considered significant.
It allows us to move preclinical nuclear medicine imaging forward with substantial reduced exposure levels while preserving image quality.

This study showed that using a clinical dPET/CT system in a large animal model might provide guidance to perform translational studies that currently are only feasible in small laboratory animals using specialized micro PET/CT systems.

In the regional image quality assessment, the skull, thoracic and lumbar spine, and proximal long bones were scored excellent and acceptable, with the thoracic and lumbar spine scoring the highest on image quality. This finding is consistent with a study in skeletally immature healthy canines (53), and a human study of the spine with $^{18}$FNaF in healthy individuals were thoracic and lumbar spine had significant higher uptake compared to the cervical spine (54). An intriguing finding of the current study was that the cervical spine images were scored excellent and acceptable for most of the samples (96%) and 4% were scored insufficient. The atlas (C1) and the axis (C2) showed an uptake similar to the skull and lower than the rest of the cervical vertebrae (C3–C7) (Table 2). This may be due to anatomical differences and blood perfusion in those vertebrae, and the fact that C1–C2 lack vertebral bodies and marrow cavities, which provide capacity for higher blood perfusion (and hence bone radiotracer uptake), in addition to having anatomically different sinuous and transverse processes. The short bones images were scored excellent and acceptable (98%) with a 2% that were scored insufficient, this small percentage may be due to the lower uptake of the distal phalanges due to a relatively decreased peripheral blood flow which leads to less radiotracer availability regionally in these areas when compared with the axial skeletal structures. Additionally, if the distal extremities were relatively colder to the axial skeleton, peripheral vasoconstriction would have decreased the relative blood flow to these regions and therefore, the $^{18}$FNaF radiotracer uptake.

Overall, ULD $^{18}$FNaF dPET imaging demonstrated the feasibility of marked radiotracer dose reduction without impairing diagnostic image quality. Additionally, the dPET image data sets were quantitatively assessed and ULD $^{18}$FNaF dPET did not significantly underrepresent SUV$_{\text{mean}}$ and SUV$_{\text{max}}$ values when compared with LD and SD. As expected in a healthy canine, the average skeletal osteoblastic activity (i.e., SUV$_{\text{mean}}$) showed no statistically significant differences among the 3 doses (Table 3). This further suggests that ULD $^{18}$FNaF dPET is feasible. In addition, quantitative assessment in terms of SUV$_{\text{max}}$ showed no statistically significant differences among SD, LD and ULD doses except in the first lumbar vertebra (Table 4). The first lumbar vertebra demonstrated SUV$_{\text{max}}$ values significantly lower on SD when compared with LD or ULD but no significant differences in SUV$_{\text{mean}}$ value were noted for these 3 doses. This may be due to an increase heterogeneity of $^{18}$FNaF uptake in the lumbar vertebrae among subjects which the SUV$_{\text{max}}$ will highlight and the SUV$_{\text{mean}}$ will not. The caudal vertebrae (tail), which contains several small bones more distally located, showed no differences among doses in our qualitative and quantitative assessments. This further supports that ULD $^{18}$FNaF dPET is sufficient for assessing normal osteoblastic activity even in small distal bones which are biomechanically active.

This study showed that using a clinical dPET system in a large animal model might provide guidance to perform translational studies that currently are only feasible in small laboratory animals using specialized micro PET/CT systems. A limitation of the study was that not all dogs received the three doses (ULD, LD, and SD); however, eight of the nine dogs received the ULD in addition to either the SD or LD. The use of a translational large animal model is expensive, requires extensive preparation and coordination, and presents more challenges when compared to smaller laboratory animals. Future studies will be needed to further assess this ULD $^{18}$FNaF dPET/CT imaging approach for oncologic and non-oncologic osteoblastic diseases in preclinical large animal models.

Ultra-low dose $^{18}$FNaF dPET/CT demonstrated a comparable diagnostic image quality and quantitative accuracy when compared with SD. This ULD dPET approach is consistent with the goals of ALARA in terms of minimizing radiation exposure not only to research subjects but also PET technologists, veterinary personnel, and caretakers.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

**ETHICS STATEMENT**

The animal study was reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of The Ohio State University.

**AUTHOR CONTRIBUTIONS**

MM and MK: study design and take responsibility for the integrity of the data analysis. MM, RM, and MK: study conduct. MM and RM: data collection. MM, RM, MA-R, SF, CW, and MK: data analysis. MM, MA-R, SF, RJ, and MK: data interpretation. MM: drafting manuscript. MM, RM, MA-R, SF, CW, RJ, and MK: revising manuscript content and approving final version of manuscript. All authors contributed to the article and approved the submitted version.

**FUNDING**

This study was supported by Award Number Grant KL2TR002734 from the National Center for Advancing Translational Sciences, Ohio Third Frontier grants TECH 10-012, TECH 11-044, and TECH 13-060 and the Wright Center of Innovation in Biomedical Imaging Development Fund. REDCap electronic data capture tools hosted at The Ohio State University and supported by CTSA grant UL1TR002733.
Funding bodies had no role in the design, data analysis, or writing of the manuscript.

ACKNOWLEDGMENTS

The authors thank George Aliulis, Jim Ellis, Dr. Katherine Binzel, and Michael Friel for operating the dPET/CT system and their assistance with radiation safety protocols, and Dr. Jun Zhang for technical support. Heather Lanksy for REDCap assistance. Corinne Uskali and the Center for Design and Manufacturing Excellence at The Ohio State University for the help and assistance designing and manufacturing the Preclinical Multimodal Imaging Positioning Device. ULAR staff for animal technical assistance.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2021.725118/full#supplementary-material

REFERENCES

1. Minamimoto R, Loening A, Barkhodari A, Mosci C, Jackson T, et al. Prospective comparison of 99mTc-MDP scintigraphy, combined 18F-NaF and 18F-FDG PET/CT, and whole-body MRI in patients with breast and prostate cancer. J Nucl Med. (2015) 56:1862–8. doi: 10.2967/jnumed.115.162610
2. Kudlarethra RK, Vinjamuri S, England A, Nightingale J, Hogg P. The role of 18F-sodium fluoride PET/CT scans in the diagnosis of age-related bone disease from breast and prostate cancer. J Nucl Med Technol. (2016) 44:217–22. doi: 10.2967/jnmt.116.176859
3. Langsteger W, Rezaei A, Pirich C, Beheshhti M. (18)F-NaF-PET/CT and (99m)Tc-MDP bone scintigraphy in the detection of bone metastases in prostate cancer. Semin Nucl Med. (2016) 46:491–501. doi: 10.1053/j.semnuclmed.2016.07.003
4. Lim I, Lindenberg ML, Mena E, Verdi M, Shih JH, Mayfiled C, et al. (18)F-Sodium fluoride PET/CT predicts overall survival in patients with advanced geriatric malignancies treated with capecitabine and nivolumab with or without ipilimumab. Eur J Nucl Mol Imaging. (2019) 47:178–184. doi: 10.1007/s00259-019-04483-5
5. Silva Mendes BI, Oliveira-Neto M, Vidigal Ferreira MJ. Sodium fluoride in cardiovascular disorders: a systematic review. J Nucl Cardiol. (2019) 26:1461–1473. doi: 10.1007/s12350-019-01832-7
6. Vancheri F, Longo G, Vancheri S, Danial JSH and Henein MY. Coronary artery microcalcification: imaging and clinical implications. Diagnostics. 2019 9:125. doi: 10.3390/diagnostics9040125
7. Creager MD, Hoh T, Hutcheson JD, Moss AJ, Schlotter F, Blaser MC, et al. (18)F-Fluoride signal amplification identifies microcalcifications associated with atherosclerotic plaque instability in position emission tomography/computed tomography images. Circ Cardiovasc Imag. (2019) 12:e007835. doi: 10.1161/CIRCIMAGING.118.007835
8. Watkins L, MacKay J, Haddock B, Mazzoli V, Uhrich S, Gold G, et al. Assessment of quantitative [18F] Sodium fluoride PET measures of knee subchondral bone perfusion and mineralization in osteoarthritic and healthy subjects. Osteoarthritis Cartilage. (2021) 29:849–58. doi: 10.1016/j.joca.2021.02.563
9. MacKay J, Watkins L, Gold G, and Kogan F. [ 18 F]NaF PET-MRI provides direct in vivo evidence of the association between bone metabolic activity and adjacent synovitis in knee osteoarthritis cross-sectional study. Osteoarthritis Cartilage. (2021) 8:SI063-4584(21)00727-5. doi: 10.1016/j.joca.2021.04.014
10. Raynor WY, Borja AJ, Hancin EC, Werner TJ, Alavi A, Revheim ME. Novel musculoskeletal and orthopedic applications of [18F] sodium fluoride PET. PET Clin. (2021) 16:295–311. doi: 10.1016/j.petr.2020.12.006
11. Khaw TH, Raynor WY, Borja AJ, Al-Zaghal A, Jonnakuti VS, Cheng N, et al. Assessing the effects of body weight on subchondral bone formation with quantitative [18F] sodium fluoride PET. Ann Nucl Med. (2020) 34:599–64. doi: 10.1007/s12149-020-01482-7
12. Tibrewala R, Pedaiva V, Bucknor M, Majumdar S. Principal component analysis of simultaneous PET-MRI reveals patterns of bone-cartilage interactions in osteoarthritis. J Magn Reson Imag. (2020) 52:1462–74. doi: 10.1002/jmri.27146
13. Menendez MI, Hettlich B, Wei I, Knopp MV. Feasibility of Na(18)F PET/CT and MRI for noninvasive in vivo quantification of bone pathophysiological bone metabolism in a canine model of post-traumatic osteoarthritis. Mol Imaging. (2017) 16:15360121171174575. doi: 10.1177/15360121177174575
14. Savic D, Pedaiva V, See Y, Yang J, Bucknor M, Franc BL, et al. Imaging bone-cartilage interactions in osteoarthritis using [18F]-NaF PET-MRI. Mol Imaging. (2016) 15:1–12. doi: 10.1177/1536012116683397
15. Haddock B, Fan AP, Jorgensen NR, Suetta C, Gold GE, Kogan F. Kinetic [18F]-fluoride of the knee in normal volunteers. Clin Nucl Med. (2019) 44:377–85. doi: 10.1097/RLU.0000000000002533
16. Tibrewala R, Bahroos E, Mehrabian H, Foreman SC, Link TM, Pedaiva V, et al. [18F]-Sodium fluoride PET/MR imaging for bone-cartilage interactions in hip osteoarthritic feasibility study. J Orthopaedic Res. (2019). doi: 10.1002/joa.2019.02.213
17. Reilly CC, Raynor WY, Hong AL, Kargilis DC, Lee JS, Alecxih AG, et al. Diagnosis and monitoring of osteoporosis with [18F]-sodium fluoride PET: an unavoidable path for the foreseeable future. Semin Nucl Med. (2018) 48:535–40. doi: 10.1053/j.semnuclmed.2018.07.007
18. Austin AG, Raynor WY, Reilly CC, Zadeh MZ, Werner TJ, Zhuang H, et al. Evolving Role of MR Imaging and PET in Assessing Osteoporosis. PET Clin. (2019) 13:41–41. doi: 10.1016/j.petr.2018.08.007
19. Raynor W, Houshmand S, Gholami S, Emamzadehfar S, Rajapakse CS, Blomberg BA, et al. Evolving Role of Molecular Imaging with [18F]-Sodium Fluoride PET as a Biomarker for Calcium Metabolism. Curr Osteoporos Rep. (2016) 14:115–25. doi: 10.1007/s11914-016-0312-5
20. Kogan F, Fan AP, Monu U, Iagaru A, Hargreaves BA, Gold GE. Quantitative imaging of bone-cartilage interactions in ACL-injured patients with PET-MRI. Osteoarthritis and cartilage / OARSI, Osteoarthritis Research Society. (2018) 26:797–6. doi: 10.1016/j.joca.2018.04.001
21. Beheshti M. (18)F-Sodium Fluoride PET/CT and PET/MR Imaging of Bone and Joint Disorders. PET Clin. (2018) 13:477–90. doi: 10.1016/j.petr.2018.05.004
22. Blau M, Nagler W, Bender MA. Fluorine-18-a new isotope for bone scanning journal of nuclear medicine: official publication, Society of Nuclear Medicine. (1962) 3:332–4.
23. Blau M, Ganatra R, Bender MA. 18F-fluoride for bone imaging Seminars in nuclear medicine. (1972) 3:231–7. doi: 10.1016/S0034-9899(72)80005-9
24. Wondergem M, van der Zant FM, Knol RJ, Burgers AM, Bos SD, Jong IL, et al. (99m)Tc-HDP bone scintigraphy and (18)F-sodiumfluoride PET/CT in primary staging of patients with prostate cancer. World J Urol. (2018) 36:27–34. doi: 10.1007/s00345-017-2096-3
25. Boellaard R, Quick HH. Current image acquisition options in PET/MR Seminars in nuclear medicine. (2015) 45:192–200. doi: 10.1053/j.semnuclmed.2014.12.001
26. Oehmigen M, Lindemann ME. Gratz M, Kirschner J, Ruhlmann V, Umutlu L, et al. Impact of improved attenuation correction featuring a bone atlas and truncation correction on PET quantification in whole-body PET/MR. Eur J Nucl Med Mol Imag. (2018) 45:642–53. doi: 10.1007/s00259-017-3864-4
27. Aasheim LB, Karlberg A, Goa PE, Häberg A, Sorhaug S. Fagerli UM, et al. PET/CT imaging:evaluation of clinical UTE-based attenuation correction. Eur J Nucl Med Mol Imag. (2015) 42:1439–46. doi: 10.1007/s00259-015-3060-3
Menendez et al. Digital-PET Sodium Fluoride Dose Reduction

28. Salvadori M, Rizzo A, Rovera G, Indovina L, Schillaci O. Radiation dose in nuclear medicine—the hybrid imaging. *La Radiologia medica.* (2019) 124:768–76. doi: 10.3231/LR15017-100989-y

29. Chawla SC, Federman N, Zhang D, Nagata K, Nuthakki S, McNitt-Gray M, et al. Estimated cumulative radiation dose from PET/CT in children with malignancies—a 5-year retrospective review. *Pediatr Radiol.* (2010) 40:681–6. doi: 10.1007/s00247-009-1434-z

30. Usmani S, Van den Wyngaert T, Ahmed N, Marafi F, Esmail A, Al Kandari F, et al. Technical feasibility, radiation dosimetry and clinical use of (18)F-sodium fluoride (NaF) in evaluation of metastatic bone disease in pediatric population. *Ann Nucl Med.* (2018) 32:594–601. doi: 10.1007/s12149-018-1279-3

31. Yang CC, Yang BC, Tu CY, Wu TH, Liu SH. Low-dose computed tomography scans with automatic exposure control for patients of different ages undergoing cardiac PET/CT and SPECT/CT. *Neurol Med Commun.* (2017) 38:54–55. doi: 10.1097/01.NMC.0000000000000079

32. Jang J, Jung SE, Jeong WK, Lim YS, Choi JI, Park MY, et al. Radiation doses of various CT protocols: a multicenter longitudinal observation study. *J Korean Med Sci.* (2016) 31:S24–31. doi: 10.3346/jkms.2016.31.S1.S24

33. Sekine T, Delso G, Zeimpekis KG, Galiza Barbosa F, Ter Voert EE, Huellner M, et al. Reduction of (18)F-FDG dose in clinical PET/MR imaging by using silicon photomultiplier detectors. *Radiology.* (2018) 286:249–59. doi: 10.1148/radiol.2017162305

34. Prieto E, García-Velloso MJ, Rodríguez-Fraile M, Morán V, Garcia-García B, Guillon E, et al. Significant dose reduction is feasible in FDG PET/CT protocols without compromising diagnostic quality. *Phys Med.* (2018) 46:134–9. doi: 10.1016/j.ejmp.2018.01.021

35. Seith F, Schmidt H, Kunz J, Kustner T, Gatisidis S, Nikolau K, et al. Simulation of tracer dose reduction in (18)F-FDG PET/MRI: effects on oncologic reading, image quality, and artifacts. *J Nucl Med.* (2017) 58:1699–705. doi: 10.2967/jnm.nm.116.184440

36. Zucchetta P, Branchini M, Zorz A, Bodanza V, Cecchin D, Paiusco M, et al. Quantitative analysis of image metrics for reduced and standard dose pediatric (18)F-FDG PET/MRI examinations. *Br J Radiol.* (2019) 92:20180438. doi: 10.1259/bjr.20180438

37. Beheishi M, Mottaghy FM, Paycha F, Behrendt FF, Van den Wyngaert, Folgeman I, et al. 18F-NaF PET/CT: EANM procedure guidelines for bone imaging. *Eur J Nucl Med Mol Imag.* (2015) 42:1767–77. doi: 10.1007/s00259-015-3138-y

38. Segall G, Delbeke D, Stabin MG. et al. SNM practice guideline for sodium 18F-fluoride PET/CT bone scans 1.0. *J Nucl Med.* (2010) 51:1813–20. doi: 10.2967/jn.109.070026

39. Ohnora J, Michaud L, Balogova S, Paycha F, Nataf V, Chauchat P, et al. Can we achieve a radionuclide radiation dose equal to or less than that of 99mTc-hydroxyethylmethane dipropionate bone scintigraphy with a low dose 18F-sodium fluoride time-of-flight PET of diagnostic quality? *Nucl Med Commun.* (2013) 34:417–25. doi: 10.1097/MNM.0b013e32835fcd9d

40. Lim R, Fahey FH, Drubach LA, Connolly LP, Treves ST. Early experience with fluorine-18 sodium fluoride bone PET in young patients with back pain. *J Pediatric Orthopedics.* (2007) 27:277–82. doi: 10.1097/BPO.0b013e318034098a

41. Marafi F, Esmail A, Rasheed R, Alkandari F, Usmani S. Novel weight-based dose threshold for 18F-NaF PET-CT imaging using advanced PET-CT systems—a potential tool for reducing radiation burden. *Nuclear Medicine communications.* (2017) 38:764–70. doi: 10.1097/MNM.0000000000000706

42. Oddstig J, Leide Svegborn S, Almqvist H, Bitzen U, Garperd S, Hedeer F, et al. Comparison of conventional and Si-photomultiplier-based PET systems for image quality and diagnostic performance. *BMC Med Imag.* (2019) 19:81. doi: 10.1186/s12880-019-0377-6

43. Zhang J, Maniawski P, Knopp MV. Performance evaluation of the next generation solid-state digital photon counting PET/CT system. *EJNMMI Res.* (2018) 8:97. doi: 10.1186/s13550-018-0448-7

44. Lopez-Mora DA, Estorch M, Fuentes-Ocampo F, Perez Garcia JI, Moral A, Carrio I. Digital PET/CT vs analogue PET/CT in a parathyroid gland study with (18)F-Fluorocholine. *Revista espanola de medicina nuclear e imagen molecular.* (2019) 38:121–2. doi: 10.1016/j.remnie.2018.10.012

45. Lopez-Mora DA, Flotats A, Fuentes-Ocampo F, Camacho V, Fernandez A, Ruiz A, et al. Comparison of image quality and lesion detection between digital and analog PET/CT. *Eur J Nucl Med Mol Imaging.* (2019) 46:1383–90. doi: 10.1007/s00259-019-4260-z

46. Fuentes-Ocampo F, Lopez-Mora DA, Flotats A, Paillahueque G, Camacho V, Duch J, et al. Digital vs. analog PET/CT: intra-subject comparison of the SUVmax in target lesions and reference regions. *European journal of nuclear medicine and molecular imaging.* (2019) 46:1745–1750. doi: 10.1007/s00259-019-04280-0

47. Wright CL, Binzel K, Zhang J, Knopp MV. Advanced functional tumor imaging and precision nuclear medicine enabled by digital PET technologies. *Contrast Media Mol Imag.* (2017) 9:20180438. doi: 10.1155/2017/20180438

48. Wright CL, Maly JJ, Zhang J, Wuthrick EJ, Knopp MV. Clinical feasibility of (90)Y digital PET/CT for imaging microsphere biodistribution following radioembolization. *Eur J Nucl Med Mol Imaging.* (2017) 44:1194–7. doi: 10.1007/s00259-017-3694-4

49. Wright CL, Maly JJ, Zhang J, Knopp MV. Advancing Precision Nuclear Medicine and Molecular Imaging for Lymphoma. *PET Clin.* (2017) 12:63–82. doi: 10.1016/j.petclin.2016.08.005

50. Menendez MI, Hettlich B, Wei L, Knopp MV. Preclinical Multimodal Molecular Imaging Using 18F-FDG PET/CT and MRI in a Phase 1 Study of a Knee Osteoarthritis in In Vivo Canine Model Mol Imaging. (2017) 16:153601217697443. doi: 10.1136/153601217697443

51. Nguyen NC, Vercher-Conejero JL, Sattar A, Miller MA, Maniawski PJ, Jordan DW, et al. Image quality and diagnostic performance of a digital pet prototype in patients with oncologic diseases: initial experience and comparison with analog PET. *J Nucl Med.* (2015) 56:1378–85. doi: 10.2967/jn.114.148338

52. Wright CL, Washington IR, Bhatt AD, Knopp MV. Emerging opportunities for digital PET/CT to advance locoregional therapy in head and neck cancer seminars in radiation. *Oncology.* (2019) 29:93–101. doi: 10.1016/j.semradonc.2018.11.005

53. Valdes-Martinez A, Kraft SL, Brundage CM, Arceneaux BK, Stewart JA, Gibbons DS. Assessment of blood pool, soft tissue, and skeletal uptake of sodium fluoride F 18 with positron emission tomography-computed tomography in four clinically normal dogs. *Am J Vet Res.* (2012) 73:1589–95. doi: 10.2460/ajvr.73.10.1589

54. Ayubcha C, Zirakchian Zadeh M, Stochkendahl MJ, Al-Zaghal A, Hartvigsen J, Knopp. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in any medium or format, are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.